F
Fluxion Biosciences
Automated patch clamp and shear flow systems
About Fluxion Biosciences
Fluxion Biosciences, founded in 2006 by Cristian Ionescu-Zanetti, Michael Schwartz, and Christopher J. Crum, develops automated systems for cellular analysis aimed at accelerating drug discovery and life science research. The company's initial technology was developed at the University of California, Berkeley. Cristian Ionescu-Zanetti has a background in Bioengineering from UC Berkeley and Applied Physics from Cornell, while Michael Schwartz's expertise lies in Bioengineering and Mechanical Engineering from UC Berkeley and MIT, respectively.
The company provides tools for functional cell analysis, operating in the life sciences and drug discovery markets. Its client base includes academic research laboratories, pharmaceutical companies, and biotechnology organizations. The business model centers on the sale of these specialized instruments and the associated consumables.
Fluxion's product portfolio includes the BioFlux system, which enables the study of cellular interactions under physiological shear flow conditions, mimicking the environment within blood vessels. This is used for research in areas such as platelet adhesion, cancer metastasis, and biofilm formation. The IonFlux system is an automated patch clamp platform that facilitates the study of ion channels, which are crucial targets in drug discovery for conditions like cardiac arrhythmias and chronic pain. Both systems are designed to improve throughput and provide more physiologically relevant data compared to traditional manual methods.
Source: Dealroom company dataNews
Open roles
Fluxion Biosciences in the San Francisco ecosystem
The Fluxion Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series B and later3 investors entered at this stage
Signet Healthcare Partners- KPKodiak Venture Partners
- CVClaremont Creek Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fluxion Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fluxion Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

